Thirona, a Dutch company specialized in artificial intelligence (AI), in a recent announcement, has stated that it has developed a new software program that can quickly detect as well as quantify lung anomalies in cystic fibrosis (CF) patients. The software works on the principles of AI algorithm, known as PRAGMA-AI. The report given by the software will allow for an analysis of CT scans that are fast and fully automated, so no human invention is needed.
According to Thirona, PRAGMA-AI can be used both in clinical trials and clinical care to improve the diagnosis, patient monitoring, and treatment planning. It allows for large-scale investigation of CF lung disease, a crucial component in evaluating new treatment. This software also simplifies the collection of patients' data, creates care guidelines, drives quality improvement, and helps physicians study CF treatment and outcomes better.
The software has an algorithm which is a set of instructions that is designed to perform specific tasks. AI algorithms can learn data and quickly perform the outputs. Thirona's new software is faster and user-friendly; it performs the specific task in several seconds and without any human assistance. PRAGMA-AI is a part of the company's LungQ software package.